119 related articles for article (PubMed ID: 9759898)
1. A RANTES-antibody fusion protein retains antigen specificity and chemokine function.
Challita-Eid PM; Abboud CN; Morrison SL; Penichet ML; Rosell KE; Poles T; Hilchey SP; Planelles V; Rosenblatt JD
J Immunol; 1998 Oct; 161(7):3729-36. PubMed ID: 9759898
[TBL] [Abstract][Full Text] [Related]
2. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway.
Challita-Eid PM; Penichet ML; Shin SU; Poles T; Mosammaparast N; Mahmood K; Slamon DJ; Morrison SL; Rosenblatt JD
J Immunol; 1998 Apr; 160(7):3419-26. PubMed ID: 9531302
[TBL] [Abstract][Full Text] [Related]
3. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
Peng LS; Penichet ML; Morrison SL
J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
[TBL] [Abstract][Full Text] [Related]
4. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
5. I-TAC/CXCL11 is a natural antagonist for CCR5.
Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
[TBL] [Abstract][Full Text] [Related]
6. Selective diapedesis of Th1 cells induced by endothelial cell RANTES.
Kawai T; Seki M; Hiromatsu K; Eastcott JW; Watts GF; Sugai M; Smith DJ; Porcelli SA; Taubman MA
J Immunol; 1999 Sep; 163(6):3269-78. PubMed ID: 10477596
[TBL] [Abstract][Full Text] [Related]
7. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
9. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.
Owais M; Arya SK
J Hum Virol; 1999; 2(5):270-82. PubMed ID: 10551733
[TBL] [Abstract][Full Text] [Related]
10. A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.
Blanpain C; Buser R; Power CA; Edgerton M; Buchanan C; Mack M; Simmons G; Clapham PR; Parmentier M; Proudfoot AE
J Leukoc Biol; 2001 Jun; 69(6):977-85. PubMed ID: 11404385
[TBL] [Abstract][Full Text] [Related]
11. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
Dela Cruz JS; Morrison SL; Penichet ML
Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
[TBL] [Abstract][Full Text] [Related]
12. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection.
Yun JJ; Whiting D; Fischbein MP; Banerji A; Irie Y; Stein D; Fishbein MC; Proudfoot AE; Laks H; Berliner JA; Ardehali A
Circulation; 2004 Feb; 109(7):932-7. PubMed ID: 14757698
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
[TBL] [Abstract][Full Text] [Related]
14. Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES.
Jia Y; Li H; Chen W; Li M; Lv M; Feng P; Hu H; Zhang L
Gene Ther; 2006 Sep; 13(18):1351-9. PubMed ID: 16708076
[TBL] [Abstract][Full Text] [Related]
15. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
[TBL] [Abstract][Full Text] [Related]
16. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
17. Human monocyte-derived dendritic cells expressing both chemotactic cytokines IL-8, MCP-1, RANTES and their receptors, and their selective migration to these chemokines.
Zhu K; Shen Q; Ulrich M; Zheng M
Chin Med J (Engl); 2000 Dec; 113(12):1124-8. PubMed ID: 11776150
[TBL] [Abstract][Full Text] [Related]
18. CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells.
Ruffing N; Sullivan N; Sharmeen L; Sodroski J; Wu L
Cell Immunol; 1998 Nov; 189(2):160-8. PubMed ID: 9790730
[TBL] [Abstract][Full Text] [Related]
19. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
20. Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors.
Sabri F; Tresoldi E; Di Stefano M; Polo S; Monaco MC; Verani A; Fiore JR; Lusso P; Major E; Chiodi F; Scarlatti G
Virology; 1999 Nov; 264(2):370-84. PubMed ID: 10562499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
